A series of new triazolederivatives were designed and synthesized on the basis of the active site of lanosterol 14α‐demethylase from Candida albicans (CACYP51). 2‐(2,4‐Difluorophenyl)‐3‐(methyl‐(3‐phenoxyalkyl)amino)‐1‐(1H‐1,2,4‐triazol‐1‐yl)propan‐2‐ols show excellent in‐vitro activity against most of the tested pathogenic fungi. The MIC80 value of compound 8a against Candida albicans is 0.01 μM